ARCHIVES

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

This article is from The Cancer Letter archive.

Vol. 32 No. 8 | August 28, 2009

Download PDF Visit The Full Archive

Related Articles

High Risk workshop Planned To Produce Monograph On Current Knowledge

October 11, 1974

New Opportunities Still Abound In Immunology Program, Terry and other NCI Executives Say

February 27, 1976

SWOG Five Drug Adjuvant Breast Study Shows Remarkable Survival For Older, Younger Women

March 30, 1979

GI Intergroup called a model for proposed scientific steering committees.

June 10, 2005

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

December 25, 2009

Katterhagen, Nelson Reelected ACCC Leaders

February 4, 1977